Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 20/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 20/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156023 | 0.82 | AKR1C3 (0.64) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL27877121 | 0.82 | AKR1C3 (0.38) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL4914159 | 0.82 | AKR1C3 (0.48) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL12982967 | 0.80 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1PTGS1AKR1C4 | |
| SCHEMBL2795502 | 0.80 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL20943248 | 0.78 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1590117 | 0.78 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL2653066 | 0.77 | GCK (0.39) | AKR1C3AKR1C2 | |
| SCHEMBL22230559 | 0.75 | AKR1C3 (0.56) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL4201800 | 0.75 | AKR1C3 (0.76) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2308840-A1 | GPCR agonists | Prosidion Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| EP-1910290-A2 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007003962-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | AKR1C3 1631/4885AKR1C2 1371/4885AKR1C1 1635/4885 |
| US-20100063081-A1 | CPCR Agonists | GPR119, GCGR, GLP1R | AKR1C3 646/4885AKR1C2 614/4885AKR1C1 701/4885 |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | AKR1C3 921/4885AKR1C2 590/4885AKR1C1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.